#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Metachromatic leukodystrophy Cerebellar ataxia Ductal adenocarcinoma of pancreas Hypochondroplasia Oesophageal atresia Ewing's sarcoma recurrent Arrhythmogenic right ventricular dysplasia Pyoderma gangrenosum Spina bifida Antiphospholipid syndrome Netherton's syndrome Ewing's sarcoma Leukocyte adhesion deficiency type I Ocular lymphoma Penile squamous cell carcinoma More trials…

    Learn about Rare Diseases

    Sjogren’s syndrome Progressive supranuclear palsy – Diagnostics Factor IX deficiency – Trials in Disease Congenital nephrogenic diabetes insipidus – Basic Information Idiopathic pulmonary fibrosis – Basic Information Acute respiratory distress syndrome – Basic Information Marginal zone lymphoma refractory – Trials in Disease Andersen-Tawil syndrome – Trials in Disease Mucopolysaccharidosis – Treatment Mitochondrial myopathy – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Alpha-Tocopherol Progesterone Ph. Eur. OLVEREMBATINIB IMB 101 Rebisufligene Etisparvovec Rbl027.2 Ds-2325A Patiromer LUTETIUM LU-177 Immunoglobulin G Atazanavir Nelarabine Charcoal, Activated ROC-101 HYDROCHLORIDE Trimetazidine Dihydrochloride IHMA-2121771-1 Lovastatin Sabatolimab Rozanolixizumab Icatibant More therapies…

    Learn about Your Condition

    Osteonecrosis of jaw Carotid arteriosclerosis Cardiac failure Chondrocalcinosis Mucopolysaccharidosis I Myositis Elderly Conjunctivitis Toxicity to various agents Head and neck cancer Adenosquamous cell lung cancer Altered state of consciousness Nervous system disorder Arterial tortuosity syndrome Chondroplasty More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Jules Bordet

Institut Jules Bordet

Mijlenmeersstraat 90, Anderlecht, 1070, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of Glofitamab with Drug Combination for Untreated Large B-Cell Lymphoma Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    • High-grade B-cell lymphoma
    Belgium Denmark France Germany Italy Poland +1

  • Study of MCLA-129 with Chemotherapy and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Carboplatin
    • Docetaxel
    • Mcla-129
    Belgium France Germany Italy The Netherlands Spain

  • Study on Cabozantinib, Nivolumab, and Ipilimumab for Patients with Advanced or Metastatic Kidney Cancer Who Have Not Received Prior Treatment

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Renal cancer metastatic
    Investigated Drugs:
    • Cabozantinib
    • Ipilimumab
    • Nivolumab
    Belgium Czechia Finland France Germany Italy +3

  • Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Nivolumab
    • Tivozanib
    Belgium Czechia France Germany Italy Poland +2

  • Study of PF-07220060 and Letrozole for Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Breast cancer metastatic
    Investigated Drugs:
    • Letrozole
    • Pf-07220060 Monohydrate
    Belgium France Germany Italy Poland Slovakia +2

  • Study on the Effects of Durvalumab, Oleclumab, and Chemotherapy in Patients with Luminal B Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    • Durvalumab
    Belgium France

  • Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Abemaciclib
    • Letrozole
    • Palbociclib
    Belgium Bulgaria Czechia Denmark Finland France +10

  • Study of BT8009 for Patients with Advanced Breast Cancer with NECTIN4 Amplification

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Breast cancer
    • Breast cancer metastatic
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • ZELENECTIDE PEVEDOTIN
    Belgium France Italy Spain

  • Study of Nivolumab and Ipilimumab for Patients with Type B3 Thymoma and Thymic Carcinoma After Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    Belgium France The Netherlands Spain

  • Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Daratumumab
    • Dexamethasone
    • Dexamethasone Ph. Eur.
    Austria Belgium Czechia Denmark France Germany +8
Previous Page
1 … 19 20 21 22
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!